Content about Biologic

May 7, 2013
U.S. to contribute to 'rapid' biosimilar market growth through 2023, study finds

The global market for biosimilars will be worth nearly $2.5 billion this year, according to a new study.

May 6, 2013
Florida legislature passes biosimilar substitution bill

Florida's state legislature approved a bill last week that will allow pharmacists to substitute biosimilars for brand name biotech drugs.

April 30, 2013
FDA approves anticoagulant-reversal product

The Food and Drug Administration has approved a drug that reverses the effects of anticoagulant drugs in patients who have suffered acute major bleeding, the agency said.

April 24, 2013
Hospira looks to U.S. as it marks European biosimilar milestone

Generic drug maker Hospira marked its fifth year marketing knock-off versions of biotech drugs in Europe Wednesday as it presented at the 2013 Biotechnology Industry Organization International Convention this week.

April 4, 2013
Florida Senate committee passes biosimilar bill

A committee of Florida's state Senate has passed a bill that could limit the use of biosimilars in the state.

March 29, 2013
FDA proposes regulations for meetings between agency, biosimilar makers

The Food and Drug Administration is seeking comment from drug makers and others concerning formal meetings between the agency and companies looking to market follow-on biologics.

March 21, 2013
Va. governor signs first state bill to limit biosimilars

Gov. Bob McDonnell of Virginia has signed into law the first bill that could limit the reach of follow-on biologics, though the bill includes a two-year sunset clause, meaning it will expire in 2015.

March 11, 2013
PhRMA: 907 biotech drugs, vaccines under development

Nearly 1,000 biotech drugs and vaccines for more than 100 diseases are currently under development, according to a new report.

March 8, 2013
Report: Biosimilars could save $20 billion per year

While the Food and Drug Administration released draft guidance on regulations for biosimilars in February 2012, the final regulations have yet to appear. But already, everyone from analysts to trade groups to drug makers is preparing for a time when knock-off versions of biotech drugs will become available.

February 28, 2013
Outlook for biosimilars remains cloudy

Biosimilar medicines have been approved and routinely prescribed in Europe for nearly seven years, and creation of a clear pathway for Food and Drug Administration review and approval of generic versions of bioengineered drugs was enshrined into law in the United States with the passage of the Patient Protection and Affordable Care Act nearly three years ago.

February 22, 2013
FDA commissioner praises generic industry's efforts on quality, shortages, follow-on biologics in GPhA speech

One of the FDA's chief duties is ensuring the quality of food and drug products, and that was the focus of a keynote address delivered at the GPhA annual meeting.

February 5, 2013
Report documents opportunities, challenges for biosimilars

A new report sheds light on some of the opportunities and challenges that exist in follow-on biologics, arguing that their opportunity to generate value depends on factors like the speed of development, clarity of regulation, ease of access and the roles of all stakeholders.

January 21, 2013
Reports: State legislation targets biosimilar substitution

While regulations for biosimilars work their way through the Food and Drug Administration, state governments are already looking at legislation concerning the substitution of biosimilars for their branded counterparts, according to a legal affairs blog focused on the FDA.

January 17, 2013
FDA approves sterile blood-plasma product

The Food and Drug Administraiton has approved a drug for replacing clotting proteins in the blood for conditions in which patients have too little of them.

November 15, 2012
Generics target specialty pharmacy with biosimilars

Perhaps the iconic scene at the end of Ridley Scott’s 1991 movie “Thelma & Louise” — with Gina Davis’ and Susan Sarandon’s characters hurdling into the Grand Canyon in a green convertible — is a good metaphor for what’s happening in the generic drug industry these days.


October 12, 2012
FDA approves new use for Genentech arthritis drug

The Food and Drug Administration has approved a new use for a drug made by Roche division Genentech.

August 30, 2012
FDA approves Teva biosimilar

The Food and Drug Administration has approved a biosimilar drug made by Teva Pharmaceutical Industries for a condition that results from certain chemotherapy treatments, the drug maker said Thursday.

August 29, 2012
Abbott's Humira gets support for expanded use

A panel of outside advisers to the Food and Drug Administration has backed wider use for Abbott Labs’ rheumatoid arthritis drug, Humira, for treating a type of inflammatory bowel disease.

August 23, 2012
J&J, GSK start phase-3 trial program for rheumatoid arthritis drug

A division of Johnson & Johnson has started a late-stage clinical trial program for a drug for rheumatoid arthritis under a partnership with British drug maker GlaxoSmithKline.

August 17, 2012
Generics offer affordability for specialty Rx

The U.S. healthcare system presents a paradox: It’s the most expensive system in the world, and yet it produces among the worst results among developed countries.

July 31, 2012
GSK begins shipping FluLaval, Fluarix for 2012-2013 flu season

Following regulatory approval by the Food and Drug Administration's Center for Biologics Evaluation and Research, GlaxoSmithKline confirmed it has begun shipping the first lots of its 2012-2013 seasonal influenza vaccines to healthcare providers and Centers for Disease Control and Prevention distribution centers.

July 17, 2012
J&J seeks approval for Simponi in ulcerative colitis

A subsidiary of Johnson & Johnson is hoping to win an additional approval for one of its drugs.

June 6, 2012
Dr. Reddy's, Merck KGaA partner on biosimilars

A generic drug maker in India and a German pharmaceutical company will collaborate to develop biosimilars.

May 31, 2012
Pharmacy groups submit recommendations to FDA as agency finalizes draft guidance for biosimilars

As the Food and Drug Administration works to finalize draft guidance related to the development of biosimilar products, pharmacy groups recently weighed in with recommendations to facilitate the entry of lower-cost products into the biologic and specialty pharmaceutical markets.

May 15, 2012
Reports: Legislation proposed for biosimilars, overseas drug manufacturers

Legislation proposed in the House of Representatives would speed up Food and Drug Administration approval of knock-off versions of vaccines and other biologics while requiring the agency to conduct more inspections of drug factories overseas, according to published reports.

© 2013 Drug Store News. All Rights Reserved.